New Entrant Makes Moves in the Toxin Market

Share This Episode

New Entrant Makes Moves in the Toxin Market


In this month’s podcast David Moatazedi joins host Grant Stevens, MD to discuss the latest developments at Evolus, his new role as CEO and how doctors are involved with the company as they prepare for commercialization in 2019.

David shares insight into their plans, an in-depth review of Evolus, its new management team and its competitive advantages. He also answers several questions that are on the top of many of our minds.

Don’t miss out and listen today.

Podcast Guest

David Moatazedi

President & CEO


David Moatazedi joined the organization as President and Chief Executive Officer in May 2018. Mr. Moatazedi formerly served as Senior Vice President of U.S. Medical Aesthetics at Allergan™, leading the entire aesthetic portfolio of brands including Botox® Cosmetic, JUVEDERM® Collection, CoolSculpting®, KYBELLA®, SkinMedica®, Latisse®, Natrelle® and Alloderm®.
Mr. Moatazedi has nearly twenty years of commercial and executive experience building multiple market-leading brands. David also led several acquisitions for Allergan, including LifeCell™ for $2.9B and ZELTIQ® Aesthetics for $2.5B.

Prior to Mr. Moatazedi’s thirteen years at Allergan, he spent six years at Novartis Pharmaceuticals. He holds an MBA in Marketing from Pepperdine University and a B.A. in Chemistry from California State University, Long Beach.